Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 50 of 56 entries
View as:

R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCL

Phase: N/A Priority: Normal
NCT ID: NCT01865110 Org: User:
Start: 11/30/13 End: 01/31/25 Due: 01/31/26

The Combination of Rad001 and Rituximab In Patients With Non-hodgkin's Lymphomas

Phase: N/A Priority: Normal
NCT ID: NCT01567475 Org: User:
Start: 12/31/11 End: 12/31/15 Due: 12/31/16

Escalating Doses of Torisel in Combination With Three Chemotherapies Regimens: R-CHOP, R-FC or R-DHA for Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL).

Phase: N/A Priority: Normal
NCT ID: NCT01389427 Org: User:
Start: 11/30/11 End: 09/30/15 Due: 09/30/16

Study of Ibrutinib in Patients With Relapsed or Refractory Primary Central Nervous Lymphoma or Intraocular Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT02542514 Org: User:
Start: 09/30/15 End: 12/01/21 Due: 12/01/22

Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or Chronic Lymphocytic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT01944943 Org: User:
Start: 02/28/13 End: 10/31/14 Due: 10/31/15

A Phase IB Study Of The BTKi CC-292 Combined With Lenalidomide In Adults Patients With Relapsed/Refractory B-Cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT01766583 Org: User:
Start: 02/28/13 End: 01/31/18 Due: 01/31/19

Efficacy of a Treatment With CHOP and Lenalidomide in First Line in Angioimmunoblastic T-cell Lymphoma (AITL)

Phase: N/A Priority: Normal
NCT ID: NCT01553786 Org: User:
Start: 11/30/11 End: 03/21/19 Due: 03/21/20

Follicular Lymphoma IV/SC Rituximab Therapy (FLIRT)

Phase: N/A Priority: Normal
NCT ID: NCT02303119 Org: User:
Start: 02/02/15 End: 06/29/21 Due: 06/29/22

Efficacy of Lenalidomide in Combination With Subcutaneous Rituximab + miniCHOP in DLBCL Patients of 80 y/o or+

Phase: N/A Priority: Normal
NCT ID: NCT02128061 Org: User:
Start: 08/31/14 End: 01/31/21 Due: 01/31/22

Breast Implant-associated Anaplastic Large Cell Lymphoma (BIA-ALCL) Registry

Phase: N/A Priority: Normal
NCT ID: NCT04220970 Org: User:
Start: 06/07/17 End: 06/07/32 Due: 06/07/33

Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT03458260 Org: User:
Start: 03/26/18 End: 03/31/25 Due: 03/31/26

Phase Ib/II Study of the Efficacy and Safety of the R-CMC544/R-GEMOX Combination in Diffuse Lage B-cell Lymphoma at First or Second Relapse

Phase: N/A Priority: Normal
NCT ID: NCT01562990 Org: User:
Start: 12/31/12 End: 03/31/16 Due: 03/31/17

Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by Chemiotherapy

Phase: N/A Priority: Normal
NCT ID: NCT02889523 Org: User:
Start: 10/31/16 End: 04/30/26 Due: 04/30/27

Study of Epcoritamab in Relapsed and Refractory Primary Diffuse Large B-cell Lymphoma of the CNS Treated With Lenalidomide and Rituximab

Phase: N/A Priority: Normal
NCT ID: NCT06931652 Org: User:
Start: 06/30/25 End: 01/31/30 Due: 01/31/31

Bendamustine Study in Classical Hodgkin Lymphoma Patients Over 60 Treated by Prednisone, Vinblastine and Doxorubicin

Phase: N/A Priority: Normal
NCT ID: NCT02414568 Org: User:
Start: 07/17/15 End: 11/10/20 Due: 11/10/21

Study Of Nivolumab Alone, Or In Combination With Vinblastin In Patients With Classical Hodgkin Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT03580408 Org: User:
Start: 08/31/18 End: 08/12/21 Due: 08/12/22

Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT06006117 Org: User:
Start: 09/05/23 End: 09/30/32 Due: 09/30/33

Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT04802590 Org: User:
Start: 01/24/22 End: 09/30/31 Due: 09/30/32

Study of Lacutamab in Peripheral T-cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT04984837 Org: User:
Start: 10/05/21 End: 01/30/28 Due: 01/30/29

Glofitamab in Real Life

Phase: N/A Priority: Normal
NCT ID: NCT06994169 Org: User:
Start: 08/01/25 End: 11/30/26 Due: 11/30/27

A Phase Ib Study of Oral Selinexor in Adult Patients With Relapsed/Refractory B-cell Lymphoma Receiving R-DHAOx or R-GDP

Phase: N/A Priority: Normal
NCT ID: NCT02741388 Org: User:
Start: 10/31/16 End: 09/29/21 Due: 09/29/22

FERtility After Therapy with Intensive Lymphoma in Young Women: LNH-03 1B, LNH-03 2B, LNH-07 3B, GAINED Follow-up

Phase: N/A Priority: Normal
NCT ID: NCT06592846 Org: User:
Start: 09/30/24 End: 01/16/25 Due: 01/16/26

Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II HL and PET Positivity After 2 Cycles of ABVD

Phase: N/A Priority: Normal
NCT ID: NCT02298283 Org: User:
Start: 04/30/15 End: 07/09/20 Due: 07/09/21

Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5

Phase: N/A Priority: Normal
NCT ID: NCT06284122 Org: User:
Start: 06/07/24 End: 04/30/34 Due: 04/30/35

A Phase II Study Evaluating Glofitamab in Combination With Venetoclax Plus Zanubrutinib or Venetoclax Alone in Subjects With Untreated or Relapsed/Refractory High-risk Mantle-cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT06558604 Org: User:
Start: 02/28/25 End: 03/31/32 Due: 03/31/33